HMN Insiders Sell as Earnings Arrive

HMN reports Q3 results today with one number standing out: insiders sold a net $1.7 million worth of stock over the past 90 days, every transaction a sale, none a purchase.

The selling has been broad. CEO Marita Zuraitis has sold shares on at least four separate occasions in October alone, disposing of roughly 7,500 shares between October 6 and October 16 at prices around $46. All of her sales were executed under a pre-arranged 10b5-1 plan, which reduces their signal value as expressions of conviction. The September activity tells a different story: director Perry Hines sold $169,000 worth of stock on September 3, and General Counsel Donald Carley sold $107,000 on the same day, both outside any declared plan. Director Thomas Bradley also sold $258,000 in mid-August without a plan. Discretionary sales by directors and officers, sold near the stock's recent highs above $50, carry more weight than the CEO's scheduled disposals.

The stock has pulled back from those September levels. HMN closed at $47.47 on November 3, down roughly 7% from the $52 range where several of the larger discretionary sales were executed. On the week it gained 2.6%, broadly in line with the median for its closest insurance peers. CNA slipped 1.1% over the same period while ALL, RLI and CB each gained 3% or more, so HMN's recovery has been middling rather than a standout. Options positioning is leaning bullish rather than cautious: the put/call ratio is at 0.65, more than a standard deviation below its 20-day average of 0.77, a shift away from the defensive posture seen in late September when the ratio briefly touched 1.32. Short interest is a non-factor at 2.5% of the free float, with borrow availability extremely loose at over 7,500%, leaving no meaningful pressure from that quarter.

Analyst coverage is sparse and somewhat dated. The most recent action on record is BMO Capital's initiation at Outperform with a $48 target in July 2025, while Raymond James held a Strong Buy with a $49 target from May 2025. Those targets now sit modestly above the current price, though the consensus was struck more than a year ago and should be read cautiously. The bull case centres on margin improvement in the property-casualty and supplemental benefits segments, plus a 25% year-on-year increase in worksite direct distribution. The bear case points to the company's narrow focus on the educator market as a structural limit on growth, alongside headwinds from annual marks that weighed on results through 2024.

The print will test whether the margin gains that drove optimism earlier in the year have continued into Q3, and whether the company's niche educator franchise can sustain the earnings-per-share trajectory that has ranked HMN in the 85th percentile for EPS surprise over its recent history.